# Selective IgA Deficiency

Confirm persistent, isolated severe IgA reduction after age 4, then distinguish uncomplicated disease from impaired antibody function, evolving CVID, secondary causes, and associated infection, autoimmune, allergic, or transfusion-risk phenotypes.

**Clinical question:** How should physicians confirm, phenotype, monitor, and manage selective IgA deficiency?

Updated: 2026-09-15T17:31:17.718208+00:00

## What matters in practice
- Diagnose SIgAD only in patients older than 4 years with serum IgA <7 mg/dL, normal IgG and IgM, normal vaccine responses, and exclusion of secondary hypogammaglobulinemia and T-cell defects. [9][18]
- Recurrent bacterial sinopulmonary infection should trigger assessment for IgG subclass deficiency and functional protein and polysaccharide antibody responses, because these coexisting defects identify a more consequential phenotype. [1][15][19]
- Use IgG-based celiac serology when IgA is deficient; IgA-tTG alone can miss celiac disease. [11][19]
- Do not use routine IVIG for isolated SIgAD; consider immunoglobulin replacement only in carefully selected severe phenotypes with a justified additional antibody defect, using a product with minimal IgA. [9][12]
- Document IgA deficiency before transfusion or immunoglobulin exposure, especially after a prior reaction; rare anti-IgA antibodies can mediate anaphylaxis with IgA-containing blood products or immunoglobulin. [4][12][13]

## Confirm isolated IgA deficiency before assigning SIgAD

A low IgA value is not sufficient to establish a primary selective antibody deficiency.

Classify SIgAD when serum IgA is <7 mg/dL in a patient older than 4 years, with normal serum IgG and IgM, normal vaccine responses, and exclusion of secondary hypogammaglobulinemia and T-cell defects. Do not apply this definitive label to younger children, in whom low IgA can be developmentally transient. [9][16][18]

Repeat quantitative serum immunoglobulins when the initial result is unexpected or obtained during an acute clinical evaluation, and interpret pediatric concentrations against age-specific laboratory reference ranges. Quantify IgG and IgM concurrently: low IgG or low IgM shifts the working diagnosis away from isolated SIgAD and toward a broader humoral immunodeficiency. [18][23]

Review medications and acquired conditions before diagnosing a primary disorder. Antiepileptic medications, microbiome disruption associated with antibiotics, infections, and malignancy have been associated with secondary IgA deficiency. [4][15]
- Obtain a CBC with differential, quantitative IgG/IgA/IgM, IgG subclasses, lymphocyte subsets, and antigen-specific responses to protein and polysaccharide antigens when IgA deficiency is clinically suspected. [15]
- Treat a low IgA result with abnormal IgG, impaired vaccine response, or lymphocyte abnormalities as an expanded immunodeficiency workup rather than isolated SIgAD. CVID requires low IgG with marked IgA reduction, exclusion of secondary causes and severe T-cell deficiency, plus severely altered vaccine response or reduced memory B cells. [18]

*Laboratory patterns that determine whether low IgA represents SIgAD or another immune phenotype. [9][15][18]*

| Pattern | Key findings | Clinical next step |
| --- | --- | --- |
| SIgAD | Age >4 years; IgA <7 mg/dL; normal IgG and IgM; normal vaccine responses; secondary causes and T-cell defects excluded. [9][18] | Phenotype infection burden, allergy, autoimmunity, gastrointestinal disease, and transfusion history. [15][18] |
| Low IgA in a child younger than 4 years | Does not meet age criterion for SIgAD. [9][18] | Use age-adjusted interpretation and reassess immunoglobulins over time if clinical infections or immune features persist. [6][23] |
| Low IgA plus impaired polysaccharide or protein antibody responses | Functional antibody defect on specific antibody testing. [15] | Assess infection severity and consider immunology-directed prevention or, rarely, immunoglobulin replacement when clinically justified. [9][15] |
| Low IgA plus low IgG | Pattern is inconsistent with isolated SIgAD; CVID criteria include low IgG with marked IgA reduction and impaired vaccine response or low memory B cells. [18] | Evaluate for CVID and secondary hypogammaglobulinemia; refer to clinical immunology. [18] |
| Low IgA after medication, infection, or malignancy | Potential secondary IgA deficiency. [4] | Identify and address the associated cause before diagnosing a primary immunodeficiency. [4][15] |

## Use phenotype to direct the workup

Most affected individuals are asymptomatic; testing and surveillance should follow the presenting clinical branch.

Incidentally identified, asymptomatic patients usually need confirmation of the immunoglobulin pattern and documentation rather than treatment. Approximately 85% to 90% of IgA-deficient individuals are asymptomatic, whereas symptomatic patients most often have recurrent respiratory or gastrointestinal infections, allergic disease, or autoimmunity. [15][16]

For recurrent otitis, sinusitis, bronchitis, or pneumonia, obtain microbiologic data during clinically significant episodes when feasible and assess functional antibody responses to protein and polysaccharide antigens. Recurrent pulmonary infections are commonly associated with encapsulated bacteria, particularly Streptococcus pneumoniae and Haemophilus influenzae; risk is greater when IgG2 or IgG3 subclass deficiency coexists. [15][19]

For chronic or recurrent diarrhea, malabsorption, or unexplained weight loss, test for Giardia lamblia and evaluate for celiac disease. SIgAD has a predilection for Giardia infection, and total IgA deficiency makes IgA-based celiac testing unreliable. [4][11][19]

For severe allergic rhinitis, asthma, eczema, urticaria, conjunctivitis, food allergy, or recurrent allergic symptoms, evaluate and treat the allergic disorder on its own merits while recognizing the association with SIgAD. For autoimmune features, use organ-directed testing based on presentation because celiac disease, thyroid disease, type 1 diabetes, systemic lupus erythematosus, autoimmune cytopenias, and inflammatory arthritis are associated conditions. [18][19]
- Order total IgA with IgA-tTG as first-line celiac testing only when IgA is adequate; if IgA is deficient, use IgG EMA, IgG deamidated gliadin peptide, or IgG-tTG testing. [11]
- Obtain IgG subclasses and specific antiprotein and antipolysaccharide antibody responses when infection frequency, severity, or pathogen pattern suggests clinically meaningful humoral dysfunction. [1][15]
- Ask specifically about prior plasma, platelet, red-cell, or immunoglobulin reactions; anaphylaxis after a blood product is an indication for immunologic evaluation for IgA deficiency. [15]

### When to escalate to immunology

Refer patients with recurrent or severe sinopulmonary infection, bronchiectasis concern, impaired vaccine responses, IgG subclass abnormalities, low IgG or IgM, lymphocyte abnormalities, anaphylaxis to blood products, or a phenotype raising concern for CVID. The referral question is whether the patient has isolated SIgAD or a broader defect requiring infection prevention or immunoglobulin replacement. [15][18]

*Presentation-driven evaluation in confirmed or suspected SIgAD. [4][11][15][18][19]*

| Clinical branch | Targeted evaluation | Interpretation and action |
| --- | --- | --- |
| Recurrent sinopulmonary infection | CBC with differential; IgG subclasses; protein and polysaccharide antigen-specific antibody responses; lymphocyte subsets. [15] | Identify coexisting subclass or functional antibody defects; escalate if vaccine responses are impaired or broader immune abnormalities are present. [1][15][18] |
| Chronic diarrhea or malabsorption | Giardia testing; total IgA; IgG EMA, IgG DGP, or IgG-tTG if IgA deficient. [4][11] | Do not rely on IgA-tTG alone in IgA deficiency. [11][19] |
| Allergic phenotype | Clinical assessment for rhinitis, asthma, eczema, urticaria, conjunctivitis, and food allergy. [19] | Treat the specific allergic disease and continue surveillance for infectious and autoimmune complications. [17][19] |
| Autoimmune phenotype | Organ-directed testing for celiac disease, thyroid disease, type 1 diabetes, lupus, arthritis, or cytopenia according to presentation. [18][19] | Manage the identified autoimmune disease while reassessing for associated immune evolution when immunoglobulin abnormalities broaden. [17][18] |
| Prior transfusion reaction | Review product exposure and reaction phenotype; evaluate IgA deficiency and involve transfusion medicine before future exposure. [13][15] | Avoid unplanned exposure to standard immunoglobulin preparations in patients at risk for anti-IgA-mediated reactions. [12][13] |

## Treat the phenotype, not the IgA value

There is no replacement therapy that corrects isolated mucosal IgA deficiency.

For isolated SIgAD without clinically consequential infections or associated disease, do not institute immunoglobulin replacement solely because the IgA concentration is low. IVIG is not indicated when selective IgA deficiency is the only abnormality of concern. [12]

For recurrent bacterial respiratory infections, treat documented infections with pathogen-directed antimicrobial therapy and determine whether impaired specific antibody responses, an IgG subclass deficiency, or evolving CVID is contributing. Prophylactic antibiotics may be appropriate in selected symptomatic patients, particularly those with a severe infectious phenotype; agent choice and regimen should be individualized to infection site, cultures, allergy history, and local resistance patterns. [4][9]

Consider immunoglobulin replacement only rarely and only when there is a justified severe phenotype with an additional clinically meaningful antibody defect. If replacement is used, select an immunoglobulin product with minimal IgA and initiate and monitor treatment under an immunodeficiency-experienced physician because hypersensitivity reactions can occur in patients with anti-IgA antibodies. [9][12]

Treat associated Giardia, celiac disease, allergic disease, and autoimmunity according to the confirmed disorder rather than attributing persistent symptoms to SIgAD alone. In celiac disease, use IgG-based serology for the diagnostic pathway when IgA deficient. [4][11][18]
- Do not prescribe standard IVIG for an isolated low IgA level without a separate replacement indication. [12]
- Before considering Ig replacement, document quantitative immunoglobulins, IgG subclasses, and functional protein and polysaccharide antibody responses. [15]
- Use infection cultures and clinical response to determine whether recurrent respiratory illness is bacterial and whether antibiotic prevention is warranted. [9][15]

*Management choices by SIgAD phenotype. [4][9][11][12][15]*

| Phenotype | Management | Avoid or reassess |
| --- | --- | --- |
| Asymptomatic isolated SIgAD | Document diagnosis, educate regarding relevant complications, and monitor clinically. [4][15] | Avoid IVIG solely for low IgA. [12] |
| Recurrent bacterial respiratory infection with otherwise normal functional evaluation | Treat episodes using microbiologic and clinical data; consider prophylactic antibiotics in selected severe phenotypes. [9][15] | Reassess for functional antibody defects if infections persist or worsen. [15] |
| SIgAD plus impaired specific antibody response or IgG subclass deficiency | Immunology-directed prevention; prophylactic antibiotics may be used, and rare cases may justify low-IgA immunoglobulin replacement. [1][9][15] | Do not assume isolated SIgAD; evaluate for broader humoral disease. [18] |
| IgA deficiency with suspected celiac disease | Use IgG EMA, IgG DGP, or IgG-tTG rather than an IgA-only serologic strategy. [11] | Do not interpret a negative IgA-tTG as exclusion of celiac disease. [11][19] |

## Plan blood-product and immunoglobulin exposure

The key safety task is identifying patients with a reaction history before another exposure.

A rare subset of patients with complete IgA deficiency develops anti-IgA antibodies, including IgE anti-IgA antibodies, that can cause severe hypersensitivity or anaphylaxis after IgA-containing blood products or immunoglobulin. A prior anaphylactic transfusion reaction should prompt formal evaluation and transfusion-medicine planning before future transfusion. [4][13][15]

Standard immunoglobulin preparations should not be used casually in SIgAD. IVIG labeling guidance states that true hypersensitivity reactions are rare but may occur in patients with anti-IgA antibodies, and IVIG is not indicated for isolated SIgAD. When an independent replacement indication is established, use a low-IgA product and supervise initiation and monitoring through an experienced immunodeficiency clinician. [9][12]

Place IgA deficiency and any prior transfusion or immunoglobulin reaction prominently in the medical record. For patients with a concerning reaction history, coordinate product selection prospectively with transfusion medicine rather than waiting until urgent transfusion is required. [13][15]
- Ask about hypotension, wheeze, urticaria, angioedema, or anaphylaxis during prior transfusion or immunoglobulin exposure. [12][13]
- Do not infer that every patient with SIgAD will react to transfusion; focus precautions on complete deficiency and especially those with prior reactions or identified anti-IgA antibodies. [4][12][13]

*Exposure decisions in patients with IgA deficiency. [4][9][12][13][15]*

| Situation | Decision | Reason |
| --- | --- | --- |
| Isolated SIgAD, no replacement indication | Do not administer IVIG for the IgA deficiency itself. [12] | IVIG is not indicated when SIgAD is the only abnormality. [12] |
| Prior anaphylaxis to a blood product | Evaluate for IgA deficiency and coordinate future transfusion planning with transfusion medicine. [13][15] | Anti-IgA antibodies can confer risk of anaphylaxis with IgA-containing products. [13] |
| Independent indication for immunoglobulin replacement | Use only after immunodeficiency-experienced supervision; choose a minimal-IgA product when justified. [9][12] | Hypersensitivity reactions are rare but can occur in patients with anti-IgA antibodies. [12] |

## Monitor for changing phenotype and broader immunodeficiency

Follow-up intensity should track infectious burden and emergence of immune-mediated disease.

Monitor symptomatic patients at regular clinical intervals for recurrent sinopulmonary infection, gastrointestinal infection, asthma or allergic rhinitis, and autoimmune disease. Infection is often the earliest manifestation in symptomatic cohorts, with allergic and autoimmune manifestations emerging later; new disease in one domain should prompt reassessment of the others. [4][17]

Repeat quantitative immunoglobulins and functional antibody assessment when infections become more frequent or severe, when new autoimmune disease develops, or when a prior isolated pattern changes. SIgAD can be an early manifestation before subsequent CVID diagnosis; falling IgG, impaired vaccine responses, or reduced memory B cells warrants reclassification rather than continued labeling as uncomplicated SIgAD. [4][18]

Patients with recurrent lower respiratory infections require particular attention because coexisting IgG subclass deficiency and defective antibody responses can identify a higher-risk phenotype. Persisting lower respiratory disease despite standard management should prompt immunology review rather than empiric indefinite treatment as uncomplicated SIgAD. [1][15][19]
- At follow-up, document interval infection number, infection site, cultured organisms, antimicrobial courses, hospitalizations, and response to preventive strategies. [9][15]
- Reassess celiac disease using IgG-based testing when compatible symptoms arise, and pursue organ-directed evaluation for thyroid disease, type 1 diabetes, lupus, arthritis, or cytopenias when clinically indicated. [11][18][19]
- Revisit transfusion precautions at transitions of care and before planned procedures likely to require blood products. [13][15]

## References
1. BTS Guideline - Thorax — thorax.bmj.com — https://thorax.bmj.com/content/thoraxjnl/74/Suppl_1/1/DC7/embed/inline-supplementary-material-7.pdf?download=true
2. P177 Selective ig a deficiency in paediatric recurrent infections – a retrospective study | Archives of Disease in Childhood — adc.bmj.com — https://adc.bmj.com/content/102/Suppl_2/A102.2
3. Immunoglobulin A deficiency in children, an undervalued clinical issue - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1521661619303390
4. The clinical implications of selective IgA deficiency - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2589909019300255
5. Selective IgA Deficiency: Epidemiology, Pathogenesis, Clinical ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdf/10.1111/sji.12499
6. Selective IgA deficiency in early life: Association to infections and allergic diseases during childhood - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1521661609006950
7. Selective Immunoglobulin A Deficiency - ScienceDirect.com — www.sciencedirect.com — https://www.sciencedirect.com/topics/immunology-and-microbiology/selective-immunoglobulin-a-deficiency
8. A novel method to standardise serum IgA measurements shows an ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1002/cti2.1344
9. Selective IgA Deficiency: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management - Yazdani - 2017 - Scandinavian Journal of Immunology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/sji.12499
10. Immunodeficiency Disorders | Pediatrics In Review - AAP Publications — publications.aap.org — https://publications.aap.org/pediatricsinreview/article/40/5/229/35282/Immunodeficiency-Disorders
11. [PDF] Coeliac disease: recognition, assessment and management | NICE — www.nice.org.uk — https://www.nice.org.uk/guidance/ng20/resources/coeliac-disease-recognition-assessment-and-management-pdf-1837325178565
12. [PDF] Guideline on core SmPC for human normal immunoglobulin for ... — www.ema.europa.eu — https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-core-summary-product-characteristics-human-normal-immunoglobulin-intravenous-administration-ivig-revision-4_en.pdf
13. [PDF] Guidelines for Preventing Opportunistic Infections Among ... - CDC — www.cdc.gov — https://www.cdc.gov/mmwr/PDF/RR/RR4910.PDF
14. Prevention of Hepatitis A Through Active or Passive Immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP) — www.cdc.gov — https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.htm
15. Selective IgA Deficiency - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2821513?term=%22J+Clin+Immunol%22%5Bjour%5D
16. Selective IgA Deficiency and COVID-19 Outcomes: A Nationwide Retrospective Cohort Study - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC13074005
17. Understanding the natural history of selective IgA deficiency - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12276590
18. The clinical implications of selective IgA deficiency - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388344
19. Selective IgA Deficiency - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/sites/books/NBK538205
20. Selective IgA Deficiency - StatPearls - NCBI Bookshelf - NIH — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK538205
21. Overlapping autoimmunity and immunodeficiency: a case of selective IgA deficiency with autoimmune hemolytic anemia - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC12930997
22. Selective IgA Deficiency May Be an Underrecognized Risk ... — www.jaci-inpractice.org — https://www.jaci-inpractice.org/article/S2213-2198(22)01043-1/fulltext
23. Immunoglobulin A Deficiency - an overview | ScienceDirect Topics — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/immunoglobulin-a-deficiency
24. IgA deficiency: clinical correlates and responses to pneumococcal ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S152166160300336X

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.